Caidya has appointed Michael Clay as Chief Operating Officer to strengthen multi-regional clinical development and operational excellence. The move reinforces Caidya’s focus on delivering integrated multi-regional clinical development solutions for biopharmaceutical companies. Moreover, the leadership appointment supports the company’s global growth strategy.
As COO, Clay will oversee global operational delivery and execution strategy. Additionally, he will enhance the client engagement model across the U.S., Europe, and Asia-Pacific. His appointment further strengthens Caidya’s ability to support innovative biotech sponsors worldwide.
Clay brings extensive experience in global project delivery and site relationship strategy. He has led large-scale programs across more than 60 countries. Furthermore, he has built high-performing delivery teams known for operational discipline and sponsor trust.
Notably, Clay has significant leadership experience in Asia-Pacific. In this region, speed, regulatory precision, and close site collaboration remain critical. His hands-on approach aligns with Caidya’s global footprint and strong presence in China. China continues to serve as a key region for biotech innovation and patient access.
Most recently, Clay served as senior vice president, Global Project Delivery at Fortrea. There, he oversaw more than 500 global clinical trials. Previously, he held COO and senior operations roles at other global CROs and site management organizations. His expertise in aligning sponsors, research sites, and cross-functional teams strengthens Caidya’s delivery model. As a result, Caidya can provide agile and integrated solutions for evolving biotech needs.
Strengthening Global Reach with Regional Expertise
“Mike’s leadership strengthens one of our most important differentiators our ability to combine global reach with regional expertise, particularly across APAC and China,” said Barbara Lopez Kunz, CEO, Caidya. “His deep understanding of site engagement, global execution, and sponsor partnership will help us scale while preserving the agility, accountability, and transparency our clients value.”
“I’m excited to join Caidya at a time when global clinical development is becoming more interconnected and more complex,” said Clay. “Caidya is strategically positioned to help sponsors accelerate programs while maintaining quality and patient focus.”
Clay’s appointment supports Caidya’s evolution as a globally integrated, mid-sized CRO. The company continues to prioritize partner-level collaboration over transactional execution. Furthermore, its APAC infrastructure and regional leadership provide sponsors access to diverse patient populations. This structure enables confident execution of complex, multi-regional trials.
The hire also reflects Caidya’s broader expansion strategy. Recently, the company added oncology and hematology SME, Edward Dow, M.D., and head of BD Europe, Mario Bautista. Several commercial executives across the U.S. also joined, each bringing over 20 years of life sciences experience.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
